• The founders saw the need for this technology and started working full-time on development in January 2015
• Filed a provisional patent by the end of February 2015
• Incorporated in mid-2016 as a California C-corporation
• The trademark for “Clear Protocol” was received in 2018
• A utility patent was issued in 2019
• A second US patent was issued in 2022
• Assembled a renowned team of subject matter experts
• Received "early-seed" capital in May 2022 and a follow-up round in September 2022 from  Ashur Capital, LLC, led by Robert Gabriel, PhD.
• In July 2022 we hired Schlesinger Group, Baltimore to conduct a survey of nearly 200 doctors. Please see our “Market Validation” page. 
• October 2022, began the development of a prototype demo application on wearables and PC
• November 2022, finalized demo application on wearables and began a trial with advisors
• January 2023, completed the trial and began the initial stages of the design and development of a commercial application
• April 2023, Regulation Crowdfunding on file with the SEC.

We started the company to overcome poor quality healthcare due to inconsistent clinical follow-through, which leads to errors and provider burnout. 

This matters to us on a personal level! We experienced a nearly tragic childbirth situation in the hospital, where we almost lost a mother and child. So, we were afraid of what could happen to one of us, or a family member. 

So: Big problem, big opportunity! We felt that solving these problems would be a major business opportunity and we went on to incorporate Clear Protocol, Inc. and patent Clear Protocol® AI.

We have key insights and a multi-disciplinary team with the right skills. Doctors, nurses, PhDs in Healthcare Informatics, Computer Science, Engineering; MBAs, Project Management, Product Development, and a passion for assistive technology. We are system integrators who know more than just hardware and software. The Clear Protocol team includes outstanding subject matter experts. They have built businesses and authored related scientific research over many years. Our patent application was processed by a U.S. “Top 100” law firm, which resulted in the successful issuance of two patents. We have continued this relationship. Please refer to the “Our Team” page.

We estimate the addressable market to be 11 million doctors and nurses in private practices, clinics, and hospitals.

Initially, the Target Market (or Serviceable Obtainable Market (SOM)) is direct sales to clinics and private doctor practices in the major metro area near our offices - over 7,000 clinics & private practices. Please refer to our presentation deck.

A “Top 100” US law firm, Sheppard Mullin, filed our patents, which were issued in 2019 and 2022.

UCLA computer science advised and programmed our working prototype.  

Since 2016, we have been collaborating with Dimitrios Zikos, Ph.D., Associate Professor, Health Administration Program, Director of Health Administration Division, Central Michigan University.

There are about twenty specialized experts who helped or are helping with development. 

We have received "early-seed" capital in May 2022 and a follow-up round in September 2022 from  Ashur Capital, LLC, led by Robert Gabriel, PhD. 

We have connections to engineering talent, medical advisors, and legal advice both corporate and intellectual property.

In 2024, we have obtained LOIs from two university-based nursing schools and a pediatrician in private practice.

Our biggest challenge is raising the target capital to stay on the current milestone projections while working on product development and marketing at the same time.

Our system design must be practical for the technical abilities and fit the ergonomics of a diverse population of clinicians.

Providing the product within the projected costs or at prices the customers are willing to pay.

There are many similar-sounding products, but we are the first to have a practical solution to this information technology problem in healthcare. We have broad, defensible patents. 

There is a strong demand to protect patients and medical personnel and reduce hospital costs. Centers for Medicare and Medicaid (CMS), and the states track re-admissions statistics, and they are severely penalizing hospitals. 

Hospitals are strongly motivated to consider our product.

We are the first with a comprehensive patented solution (two issued US Utility Patents). Healthcare has an information bottleneck at the point of care, decades in the making. The innovation of Clear Protocol® is to enable a clinician at the point of care to contemporaneously verify and log a procedure, potentially saving valuable time. Hospitals also can expect ongoing cost reductions and many other benefits.

Customer acquisition is more of an issue for B2C (business-to-consumer) companies. However, Clear Protocol® is business-to-business, so the ratio is more favorable. The lifetime value of even the smallest customer (a solo physician practice) is in the thousands because all the staff will be using our product every workday. Our cost to acquire a customer will be comparatively low – mainly the initial engagement. After that, the customer pays an ongoing monthly fee to cover the maintenance. Customization, installation, and training will be charged separately. Since profit is derived mostly from scalable software, the incremental costs of adding customers are minimal, and the margins are excellent. 

FDA clearance is not required. The Clear Protocol ® IT (information technology) system is NOT regulated as a typical device. We will be seeking routine HIPAA certification.

The competition is the existing software on various electronic devices: 1) a desktop computer, 2) a laptop computer, 3) a tablet, or 4) a smartphone. These are not practical at the patient’s bedside due to potential hand contamination, the inconvenience of being out of reach, or out of view, interruption, and distraction. 

Often it is impractical for clinicians to walk over to a PC or hold a mobile device in their hands and so they work by memory. Later, when recording the data into the EHR, it is only what they can recall. 

Please refer to the headings in BOLD that correspond to each quote.

CDC 2024. Centers for Disease Control and Prevention, Implementing Clinical Decision Support Systems, see the first sentence of the second paragraph, “The evidence base demonstrating the effectiveness of CDSS [Clinical Decision Support Systems] is very strong.” The statement was made in reference to Clinical Decision Support (CDS), the area of Healthcare IT for Clear Protocol®. https://hdsbpc.cdc.gov/s/article/Evidence-of-Effectiveness-for-Clinical-Decision-Support-Systems  Accessed November 12th, 2024.

HIMSS 2022 Health Information & Management Systems Society 2022 State of Healthcare Report,“99% of U.S.-based health system leaders ...agree that it’s important for their organizations to actively invest in digital transformation". Download at: https://www.himss.org/SoH-Report, quote located on page 2, in the fifth paragraph titled "Digital Transformation". Accessed November 12th, 2024.

ONC 2024 Office of the National Coordinator for Healthcare IT. "Clinical decision support (CDS) can significantly impact improvements in quality, safety, efficiency, and effectiveness of health care." The statement was made in reference to Clinical Decision Support (CDS), the area of Healthcare IT for Clear Protocol® AI. See the first sentence of the 2nd paragraph, entitled “Clinical Decision Support Promotes Patient Safety”. https://www.healthit.gov/topic/safety/clinical-decision-support  Accessed November 12th, 2024.